Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. / Iversen, Kasper; Ihlemann, Nikolaj; Gill, Sabine U; Madsen, Trine; Elming, Hanne; Jensen, Kaare T; Bruun, Niels E; Høfsten, Dan E; Fursted, Kurt; Christensen, Jens J; Schultz, Martin; Klein, Christine F; Fosbøll, Emil L; Rosenvinge, Flemming; Schønheyder, Henrik C; Køber, Lars; Torp-Pedersen, Christian; Helweg-Larsen, Jannik; Tønder, Niels; Moser, Claus; Bundgaard, Henning.

In: The New England Journal of Medicine, Vol. 380, No. 5, 2019, p. 415-424.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Iversen, K, Ihlemann, N, Gill, SU, Madsen, T, Elming, H, Jensen, KT, Bruun, NE, Høfsten, DE, Fursted, K, Christensen, JJ, Schultz, M, Klein, CF, Fosbøll, EL, Rosenvinge, F, Schønheyder, HC, Køber, L, Torp-Pedersen, C, Helweg-Larsen, J, Tønder, N, Moser, C & Bundgaard, H 2019, 'Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis', The New England Journal of Medicine, vol. 380, no. 5, pp. 415-424. https://doi.org/10.1056/NEJMoa1808312

APA

Iversen, K., Ihlemann, N., Gill, S. U., Madsen, T., Elming, H., Jensen, K. T., Bruun, N. E., Høfsten, D. E., Fursted, K., Christensen, J. J., Schultz, M., Klein, C. F., Fosbøll, E. L., Rosenvinge, F., Schønheyder, H. C., Køber, L., Torp-Pedersen, C., Helweg-Larsen, J., Tønder, N., ... Bundgaard, H. (2019). Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. The New England Journal of Medicine, 380(5), 415-424. https://doi.org/10.1056/NEJMoa1808312

Vancouver

Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. The New England Journal of Medicine. 2019;380(5):415-424. https://doi.org/10.1056/NEJMoa1808312

Author

Iversen, Kasper ; Ihlemann, Nikolaj ; Gill, Sabine U ; Madsen, Trine ; Elming, Hanne ; Jensen, Kaare T ; Bruun, Niels E ; Høfsten, Dan E ; Fursted, Kurt ; Christensen, Jens J ; Schultz, Martin ; Klein, Christine F ; Fosbøll, Emil L ; Rosenvinge, Flemming ; Schønheyder, Henrik C ; Køber, Lars ; Torp-Pedersen, Christian ; Helweg-Larsen, Jannik ; Tønder, Niels ; Moser, Claus ; Bundgaard, Henning. / Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. In: The New England Journal of Medicine. 2019 ; Vol. 380, No. 5. pp. 415-424.

Bibtex

@article{c6b81d4321524a26a483363334acf6dc,
title = "Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis",
abstract = "BACKGROUND: Patients with infective endocarditis on the left side of the heart are typically treated with intravenous antibiotic agents for up to 6 weeks. Whether a shift from intravenous to oral antibiotics once the patient is in stable condition would result in efficacy and safety similar to those with continued intravenous treatment is unknown.METHODS: In a randomized, noninferiority, multicenter trial, we assigned 400 adults in stable condition who had endocarditis on the left side of the heart caused by streptococcus, Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative staphylococci and who were being treated with intravenous antibiotics to continue intravenous treatment (199 patients) or to switch to oral antibiotic treatment (201 patients). In all patients, antibiotic treatment was administered intravenously for at least 10 days. If feasible, patients in the orally treated group were discharged to outpatient treatment. The primary outcome was a composite of all-cause mortality, unplanned cardiac surgery, embolic events, or relapse of bacteremia with the primary pathogen, from the time of randomization until 6 months after antibiotic treatment was completed.RESULTS: After randomization, antibiotic treatment was completed after a median of 19 days (interquartile range, 14 to 25) in the intravenously treated group and 17 days (interquartile range, 14 to 25) in the orally treated group (P=0.48). The primary composite outcome occurred in 24 patients (12.1%) in the intravenously treated group and in 18 (9.0%) in the orally treated group (between-group difference, 3.1 percentage points; 95% confidence interval, -3.4 to 9.6; P=0.40), which met noninferiority criteria.CONCLUSIONS: In patients with endocarditis on the left side of the heart who were in stable condition, changing to oral antibiotic treatment was noninferior to continued intravenous antibiotic treatment. (Funded by the Danish Heart Foundation and others; POET ClinicalTrials.gov number, NCT01375257 .).",
keywords = "Administration, Intravenous, Administration, Oral, Aged, Anti-Bacterial Agents/administration & dosage, Bacteremia/drug therapy, Endocarditis, Bacterial/drug therapy, Female, Heart Valve Prosthesis/microbiology, Humans, Intention to Treat Analysis, Kaplan-Meier Estimate, Length of Stay, Male, Middle Aged, Recurrence",
author = "Kasper Iversen and Nikolaj Ihlemann and Gill, {Sabine U} and Trine Madsen and Hanne Elming and Jensen, {Kaare T} and Bruun, {Niels E} and H{\o}fsten, {Dan E} and Kurt Fursted and Christensen, {Jens J} and Martin Schultz and Klein, {Christine F} and Fosb{\o}ll, {Emil L} and Flemming Rosenvinge and Sch{\o}nheyder, {Henrik C} and Lars K{\o}ber and Christian Torp-Pedersen and Jannik Helweg-Larsen and Niels T{\o}nder and Claus Moser and Henning Bundgaard",
year = "2019",
doi = "10.1056/NEJMoa1808312",
language = "English",
volume = "380",
pages = "415--424",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
number = "5",

}

RIS

TY - JOUR

T1 - Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis

AU - Iversen, Kasper

AU - Ihlemann, Nikolaj

AU - Gill, Sabine U

AU - Madsen, Trine

AU - Elming, Hanne

AU - Jensen, Kaare T

AU - Bruun, Niels E

AU - Høfsten, Dan E

AU - Fursted, Kurt

AU - Christensen, Jens J

AU - Schultz, Martin

AU - Klein, Christine F

AU - Fosbøll, Emil L

AU - Rosenvinge, Flemming

AU - Schønheyder, Henrik C

AU - Køber, Lars

AU - Torp-Pedersen, Christian

AU - Helweg-Larsen, Jannik

AU - Tønder, Niels

AU - Moser, Claus

AU - Bundgaard, Henning

PY - 2019

Y1 - 2019

N2 - BACKGROUND: Patients with infective endocarditis on the left side of the heart are typically treated with intravenous antibiotic agents for up to 6 weeks. Whether a shift from intravenous to oral antibiotics once the patient is in stable condition would result in efficacy and safety similar to those with continued intravenous treatment is unknown.METHODS: In a randomized, noninferiority, multicenter trial, we assigned 400 adults in stable condition who had endocarditis on the left side of the heart caused by streptococcus, Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative staphylococci and who were being treated with intravenous antibiotics to continue intravenous treatment (199 patients) or to switch to oral antibiotic treatment (201 patients). In all patients, antibiotic treatment was administered intravenously for at least 10 days. If feasible, patients in the orally treated group were discharged to outpatient treatment. The primary outcome was a composite of all-cause mortality, unplanned cardiac surgery, embolic events, or relapse of bacteremia with the primary pathogen, from the time of randomization until 6 months after antibiotic treatment was completed.RESULTS: After randomization, antibiotic treatment was completed after a median of 19 days (interquartile range, 14 to 25) in the intravenously treated group and 17 days (interquartile range, 14 to 25) in the orally treated group (P=0.48). The primary composite outcome occurred in 24 patients (12.1%) in the intravenously treated group and in 18 (9.0%) in the orally treated group (between-group difference, 3.1 percentage points; 95% confidence interval, -3.4 to 9.6; P=0.40), which met noninferiority criteria.CONCLUSIONS: In patients with endocarditis on the left side of the heart who were in stable condition, changing to oral antibiotic treatment was noninferior to continued intravenous antibiotic treatment. (Funded by the Danish Heart Foundation and others; POET ClinicalTrials.gov number, NCT01375257 .).

AB - BACKGROUND: Patients with infective endocarditis on the left side of the heart are typically treated with intravenous antibiotic agents for up to 6 weeks. Whether a shift from intravenous to oral antibiotics once the patient is in stable condition would result in efficacy and safety similar to those with continued intravenous treatment is unknown.METHODS: In a randomized, noninferiority, multicenter trial, we assigned 400 adults in stable condition who had endocarditis on the left side of the heart caused by streptococcus, Enterococcus faecalis, Staphylococcus aureus, or coagulase-negative staphylococci and who were being treated with intravenous antibiotics to continue intravenous treatment (199 patients) or to switch to oral antibiotic treatment (201 patients). In all patients, antibiotic treatment was administered intravenously for at least 10 days. If feasible, patients in the orally treated group were discharged to outpatient treatment. The primary outcome was a composite of all-cause mortality, unplanned cardiac surgery, embolic events, or relapse of bacteremia with the primary pathogen, from the time of randomization until 6 months after antibiotic treatment was completed.RESULTS: After randomization, antibiotic treatment was completed after a median of 19 days (interquartile range, 14 to 25) in the intravenously treated group and 17 days (interquartile range, 14 to 25) in the orally treated group (P=0.48). The primary composite outcome occurred in 24 patients (12.1%) in the intravenously treated group and in 18 (9.0%) in the orally treated group (between-group difference, 3.1 percentage points; 95% confidence interval, -3.4 to 9.6; P=0.40), which met noninferiority criteria.CONCLUSIONS: In patients with endocarditis on the left side of the heart who were in stable condition, changing to oral antibiotic treatment was noninferior to continued intravenous antibiotic treatment. (Funded by the Danish Heart Foundation and others; POET ClinicalTrials.gov number, NCT01375257 .).

KW - Administration, Intravenous

KW - Administration, Oral

KW - Aged

KW - Anti-Bacterial Agents/administration & dosage

KW - Bacteremia/drug therapy

KW - Endocarditis, Bacterial/drug therapy

KW - Female

KW - Heart Valve Prosthesis/microbiology

KW - Humans

KW - Intention to Treat Analysis

KW - Kaplan-Meier Estimate

KW - Length of Stay

KW - Male

KW - Middle Aged

KW - Recurrence

U2 - 10.1056/NEJMoa1808312

DO - 10.1056/NEJMoa1808312

M3 - Journal article

C2 - 30152252

VL - 380

SP - 415

EP - 424

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 5

ER -

ID: 229749977